Mode
Text Size
Log in / Sign up
N/A N=75 Randomized Treatment

Comparison of Acetaminophen and PRP Therapy for Knee OA

Knee Osteoarthritis

Enrolled (actual)
75
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcome: Primary: Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) — 3.0; 2.9; 8.0; 7.4 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Intra-articular injection of PRP (Procedure); Acetaminophen (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Primary completion
Aug 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC)
1.9; 0.8; 5.3; 2.9; 16.7; 7.9
PRIMARY
Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC)
1.9; 0.8; 5.3; 2.9; 16.7; 7.9
PRIMARY
Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC)
1.9; 0.8; 5.3; 2.9; 16.7; 7.9
PRIMARY
Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC)
1.9; 0.8; 5.3; 2.9; 16.7; 7.9
SECONDARY
Change in Visual Analog Scale (VAS)
5.9; 4.9; 3.8; 1.9; 4.1; 1.9

Summary

The purpose of this study is to test whether the platelet-rich plasma (PRP) intra-articular injection therapy is effective as an alternative treatment option in patients with mild knee osteoarthritis within a controlled randomized study compared to first line treatment acetaminophen. The investigators will evaluate patients outcome in level of pain, knee function and quality of life before the treatment and at 6, 12 and 24 weeks follow up. The study will be complemented with in vitro experiments of human osteoarthritic cartilage explants culture (treated with PRP) for histological and gene expression assays. PRP intra-articular injections therapy is effective in patients with mild knee osteoarthritis by modifying the biochemical joint environment and cartilage regeneration capability.

Eligibility Criteria

Inclusion Criteria

  • Older than 18 years old
  • Patients who haven't received steroids injection or medical treatment 1 month before the study
  • Patients with knee osteoarthritis grade I and II (Kellgren-Lawrence scale)
  • Indistinct gender
  • Patients who accept to participate in the study with previous signed informed consent

Exclusion Criteria

  • Patients with knee osteoarthritis grade III and IV (Kellgren-Lawrence scale)
  • Patients with prosthesis
  • Pregnancy
  • Patients with rheumatic diseases
  • Patients with diabetes, hepatic diseases, coagulopathy, cardiovascular diseases, immunosuppression, infections
  • Patients taking anticoagulants
  • Patients with concentrations of hemoglobin under 11 g/dL and platelets under 150,000/uL
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01782885). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search